- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

Almirall enters into license agreement with Novo Nordisk

Almirall has entered into an exclusive license agreement with Novo Nordisk for rights to the IL-21 blocking monoclonal antibody NN-8828, obtaining global rights to develop and commercialise it in certain fields, including immune inflammatory dermatological diseases.

Almirall will accelerate the development of the asset to address key dermatological diseases, taking responsibility for the global development and future commercialisation in these indications. Novo Nordisk will receive an upfront payment, as well as additional development and commercial milestone payments, and tiered royalties based upon future global sales.

NN-8828 is a first-in-class in dermatology, high affinity monoclonal antibody that targets the cytokine IL-21 and has been developed by Novo Nordisk up to Phase ll in non-dermatological indications. It has the potential to block the activation of the downstream signaling pathways of IL-21 and inhibit the pathophysiological functions induced by this cytokine in several immune cells. This differentiated mechanism makes NN-8828 a promising option for the treatment of inflammatory and autoimmune skin disorders.

Dr Karl Ziegelbauer, Chief Scientific Officer of Almirall said: “We are dedicated to developing the best possible treatments for patients suffering from skin diseases. This new partnership builds on our innovation strategy and will allow us to explore the innovative approach of IL-21 blockage as a possible new pathway to effectively treat a range of dermatological diseases.”

- Advertisement -
Joanna Harvey
Joanna Harvey
Marketing and Communication Executive | Uniphar Commercial

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription